Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China

被引：0
作者：
Huang, Kun [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Pediat, Sch Med, 1367 Wenyi West Rd, Hangzhou 311121, Zhejiang, Peoples R China
来源：
ADVANCES IN THERAPY | 2024年 / 41卷 / 04期
关键词：
Hemophilia A; Pharmacokinetics; Cost-effectiveness; Prophylaxis; Bleeding;
D O I：
10.1007/s12325-024-02786-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：1759 / 1761
页数：3
相关论文
共 50 条
[31]   A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom [J].
Bentley A. ;
Filipovic I. ;
Gooch K. ;
Büsch K. .
Health Economics Review, 3 (1) :1-12
[32]   Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease [J].
Miners, AH ;
Sabin, CA ;
Tolley, KH ;
Lee, CA .
JOURNAL OF INTERNAL MEDICINE, 1998, 244 (06) :515-522
[33]   Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK [J].
Kragh, Nana ;
Tytula, Anna ;
Pochopien, Michal ;
Aballea, Samuel ;
Toumi, Mondher ;
Hakimi, Zalmai ;
Nazir, Jameel ;
Bystricka, Linda ;
Fatoye, Francis .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (03) :262-270
[34]   Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis [J].
Chonlatis Srichumpuang ;
Arunothai Rakmanotham ;
Chatphatai Moonla ;
Darintr Sosothikul .
Orphanet Journal of Rare Diseases, 19
[35]   Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: A cost-effectiveness analysis [J].
Freedberg, KA ;
Cohen, CJ ;
Barber, TW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 15 (04) :275-282
[36]   Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis [J].
Srichumpuang, Chonlatis ;
Rakmanotham, Arunothai ;
Moonla, Chatphatai ;
Sosothikul, Darintr .
ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
[37]   Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients [J].
Wade, WE ;
Chisholm, MA .
THROMBOSIS RESEARCH, 1999, 94 (01) :65-68
[38]   Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic [J].
Hemati, Homa ;
Nosrati, Marzieh ;
Hasanzad, Mandana ;
Rahmani, Parham ;
Fariman, Soroush ;
Sarabi, Mohadese ;
Shirvani, Sepideh ;
Sadeghipour, Parham ;
Nikfar, Shekoufeh .
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01)
[39]   Cost-effectiveness of Dalteparin Versus Unfractionated Heparin as Venous Thromboembolism Prophylaxis in Malignant Gynecologic Surgery [J].
Wade, William E. ;
Spruill, William J. .
AMERICAN JOURNAL OF THERAPEUTICS, 2008, 15 (06) :512-515
[40]   Cost-Effectiveness Analysis of Micafungin Versus Fluconazole for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation in Korea [J].
Sohn, Hyun Soon ;
Lee, Tae-Jin ;
Kim, Jinhyun ;
Kim, Donghwan .
CLINICAL THERAPEUTICS, 2009, 31 (05) :1105-1115
12345